1. Bystryn J-C, Shapiro RL, Oratz R (1995) Cancer vaccines: clinical applications: partially purified tumor antigen vaccines. In: DeVita V, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer, 2nd edn. Lippincott, Philadelphia, pp 668?679
2. Bystryn J-C, Oratz R, Shapiro RL, Harris MN, Roses DF, Zeleniuch-Jacquotte A, Chen DL, Rivas MC (1999) Double-blind, placebo-controlled trial of a shed, polyvalent, melanoma vaccine in stage III melanoma. Proc Am Soc Clin Oncol 434:1673
3. DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O?Day SJ, Wanek LA, Stern SL, Morton DL (2002) Enhanced humoral immune response correlates with improved disease-free and overall survival in American joint committee on cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 20:3242?3248
4. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 8:630?641
5. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, Lemonnier FA, Davoust J, Miconnet I, Vonderheide RH, Kosmatopoulos K (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425?433